Preparation, Evaluation and Bioavailability Studies of Eudragit Coated PLGA Nanoparticles for Sustained Release of Eluxadoline for the Treatment of Irritable Bowel Syndrome.

Front Pharmacol · 2017 · PMC5702012 · PMID 29209215

Europe PMC DOI

hedged sentence

0.0010

closest p · 0.0× alpha

0.0010

boldest claim

The sentences

extremely significantP < 0.001actually significant

AUC0-last of normal drug suspension, F3 and F3C was recorded as 5.96, 40.10, and 110.57 ng.h/ml, respectively, whereas AUC 0-inf were recorded as 7.30, 54.57, and 120.05 ng.h/ml, respectively, and both were extremely significant ( P < 0.001) as compared to ELUX suspension.

also in 3,675 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.